1. In Vivo

Deals in Depth: June 2023

 
• By Maureen Riordan and Deanna Kamienski

Three $1bn+ alliances were penned in June. Topping the list was a potential $2.5bn deal under which Bausch & Lomb acquired Novartis’ Xiidra (lifitegrast ophthalmic solution) for signs and symptoms of dry eye disease; investigational compounds SAF312 (libvatrep) for chronic ocular surface pain and OJL332 for an undisclosed ophthalmic indication; plus rights to use the AcuStream delivery device in dry eye indications.

Deals In Depth

In the top June M&A by deal value, Novartis entered into an agreement to acquire Chinook Therapeutics for $3.5bn. Founded in 2019, Chinook is developing precision medicines for rare, severe chronic kidney diseases. The company's lead clinical program, atrasentan, is an endothelin A receptor antagonist that was in-licensed from AbbVie in 2019. The Phase III ALIGN trial of atrasentan is currently enrolling patients with IgA nephropathy and the Phase II AFFINITY trial of atrasentan is currently enrolling patients with proteinuric glomerular diseases. Chinook’s diversified pipeline of programs for rare, severe chronic kidney diseases will expand the Novartis renal portfolio, complementing its existing pipeline. Financing reached $7.2bn in biopharma, $458m in device, and $110m in diagnostics.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.